Page 17 - Read Online
P. 17

Page 12 of 17                       Gabriele et al. J Cancer Metastasis Treat 2018;4:17  I  http://dx.doi.org/10.20517/2394-4722.2018.06

               24.  Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab
                   Care 2006;9:358-65.
               25.  Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung
                   AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Fatty acid synthase: a metabolic
                   enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009;101:519-32.
               26.  Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011;223:283-94.
               27.  Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase
                   inhibition can suppress tumor cell growth. Cancer Cell 2005;8:311-21.
               28.  Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, Verhoeven G, Swinnen JV. Chemical inhibition of acetyl-
                   CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007;67:8180-7.
               29.  Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer
                   cell line LNCaP. Cancer Res 1997;57:1086-90.
               30.  Farese RV Jr, Walther TC. Lipid droplets finally get a little R-E-S-P-E-C-T. Cell 2009;139:855-60.
               31.  Brasaemle DL. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid
                   droplets and control of lipolysis. J Lipid Res 2007;48:2547-59.
               32.  Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism.
                   Nature 2009;458:1131-5.
               33.  Rodriguez-Navarro JA, Cuervo AM. Autophagy and lipids: tightening the knot. Semin Immunopathol 2010;32:343-53.
               34.  Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition
                   interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther 2010;9:1740-54.
               35.  Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R. De novo lipogenesis protects cancer cells from free radicals and
                   chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010;70:8117-26.
               36.  Shi Y, Han JJ, Tennakoon JB, Mehta FF, Merchant FA, Burns AR, Howe MK, McDonnell DP, Frigo DE. Androgens promote prostate
                   cancer cell growth through induction of autophagy. Mol Endocrinol 2013;27:280-95.
               37.  Zheng X, Cui XX, Gao Z, Zhao Y, Shi Y, Huang MT, Liu Y, Wagner GC, Lin Y, Shih WJ, Rao CV, Yang CS, Conney AH. Inhibitory
                   effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent
                   LNCaP prostate tumors to androgen independence. Exp Ther Med 2011;2:221-8.
               38.  Toepfer N, Childress C, Parikh A, Rukstalis D, Yang W. Atorvastatin induces autophagy in prostate cancer PC3 cells through activation
                   of LC3 transcription. Cancer Biol Thervol 2011;12:691-9.
               39.  Peng X, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL. Inhibition of proliferation and induction of autophagy by atorvastatin
                   in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. PLoS One 2013;8:e70442.
               40.  Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen
                   ablation. Cancer Res 1990;50:3748-53.
               41.  Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009;5:1403-13.
               42.  Gleave ME, Bruchovsky N, Moore MJ, Venner P. Prostate cancer: 9. Treatment of advanced disease. CMAJ 1999;160:225-32.
               43.  Boccon-Gibod L, van der Meulen E, Persson BE. An update on the use of gonadotropin-hormone antagonists in prostate cancer. Ther
                   Adv Urol 2011;3:127-40.
               44.  Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013;39:275-89.
               45.  Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ,
                   Gleave ME, Nelson PS. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression:
                   therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033-41.
               46.  Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem
                   2011;57:1366-75.
               47.  Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin
                   Cancer Res 2009;15:4792-8.
               48.  Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate
                   progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3’-kinase
                   pathway. Endocrinology 2000;141:2257-65.
               49.  Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Heat shock protein 27 increases
                   after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64:6595-602.
               50.  Ziparo E, Petrungaro S, Marini ES, Starace D, Conti S, Facchiano A, Filippini A, Giampietri C. Autophagy in prostate cancer and
                   androgensuppressiontherapy. Int J Mol Sci 2013;14:12090-106.
               51.  Li M, Jiang X, Liu D, Na Y, Gao GF, Xi Z. Autophagy protects LNCaP cells under androgen deprivation conditions. Autophagy
                   2008;4:54-60.
               52.  Bennett HL, Fleming JT, O’Prey J, Ryan KM, Leung HY. Androgens modulate autophagy and cell death via regulation of the
                   endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis 2010;1:e72.
               53.  Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;45:1069-75.
               54.  Deter RL, Baudhuin P, De Duve C. Participation of lysosomes in cellular autophagy induced in rat liver by glucagon.. J Cell Biol
                   1967;35:C11-6.
               55.  Cuervo AM. Autophagy: many paths to the same end. Mol Cell Biochem 2004;263:55-72.
   12   13   14   15   16   17   18   19   20   21   22